Penn Medicine Abramson Cancer Center

Philadelphia, Pennsylvania 19104

3 studies enrolling now · 6 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Renal Cell Carcinoma, BRCA1 Mutation, BRCA2 Mutation, Bladder Cancer, High-Risk Cancer, Metastatic Castration-resistant Prostate Neoplasms, Prostate Cancer, Prostatic Adenocarcinoma, Renal Cell Carcinoma, Clear Cell

Studies at this site

• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents — Recruiting now
• A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) — Recruiting now
• Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations — Running, not enrolling
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial — Paused
• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing — Completed